-
Toward a Universal Definition of Etiologies in Heart Failure: Categorizing Causes and Advancing Registry Science Circ. Heart Fail. (IF 9.7) Pub Date : 2024-04-16 Anubha Agarwal, Jasper Tromp, Wael Almahmeed, Christiane Angermann, Chanchal Chandramouli, Hyunjai Cho, Don-Ju Choi, Albertino Damasceno, Gerasimos Filippatos, Gregg C. Fonarow, Sivadasanpillai Harikrishnan, Lars Lund, Fred Masoudi, George A. Mensah, Asad Pathan, Pablo Perel, Fausto Pinto, Antonio Luiz Ribeiro, Stuart Rich, Yasuhiko Sakata, Karen Sliwa, Johan Sundstrom, Renee Wong, Clyde Yancy, Kelvin
Heart failure (HF) is a well-described final common pathway for a broad range of diseases however substantial confusion exists regarding how to describe, study, and track these underlying etiologic conditions.We describe (1) the overlap in HF etiologies, comorbidities, and case definitions as currently used in HF registries led or managed by members of the global HF roundtable; (2) strategies to improve
-
Early Outcomes in Patients With LVAD Undergoing Heart Transplant via Use of the SherpaPak Cardiac Transport System Circ. Heart Fail. (IF 9.7) Pub Date : 2024-04-11 Joseph B. Lerman, Chetan B. Patel, Sarah Casalinova, Alina Nicoara, Christopher L. Holley, Marzia Leacche, Scott Silvestry, Andreas Zuckermann, David A. D’Alessandro, Carmelo A. Milano, Jacob N. Schroder, Adam D. DeVore
BACKGROUND:Heart transplant (HT) in recipients with left ventricular assist devices (LVADs) is associated with poor early post-HT outcomes, including primary graft dysfunction (PGD). As complicated heart explants in recipients with LVADs may produce longer ischemic times, innovations in donor heart preservation may yield improved post-HT outcomes. The SherpaPak Cardiac Transport System is an organ
-
Early Serial Assessment of Aggregate Vasoactive Support and Mortality in Cardiogenic Shock: Insights from the Critical Care Cardiology Trials Network Registry Circ. Heart Fail. (IF 9.7) Pub Date : 2024-04-08 Siddharth M. Patel, David D. Berg, Erin A. Bohula, Vivan M. Baird-Zars, Gregory W. Barsness, Sunit-Preet Chaudhry, Meshe D. Chonde, Howard A. Cooper, Curtis Ginder, Jacob C. Jentzer, Michael C. Kontos, P. Elliott Miller, L. Kristin Newby, Connor G. O'Brien, Jeong-Gun Park, Matthew J. Pierce, Barbara A. Pisani, Brian J. Potter, Kevin S. Shah, Jeffrey J. Teuteberg, Jason N. Katz, Sean van Diepen, David
Background: Associations of early changes in vasoactive support with cardiogenic shock (CS) mortality remain incompletely defined.Methods: The Critical Care Cardiology Trials Network is a multicenter registry of cardiac intensive care units (CICUs). Patients admitted with CS (2018-2023) had vasoactive dosing assessed at 4 and 24 hours (h) from CICU admission and quantified by the vasoactive-inotropic
-
SPECTRA Phase 2b Study: Impact of Sotatercept on Exercise Tolerance and Right Ventricular Function in Pulmonary Arterial Hypertension Circ. Heart Fail. (IF 9.7) Pub Date : 2024-04-04 Aaron B. Waxman, David M. Systrom, Solaiappan Manimaran, Janethe de Oliveira Pena, Jonathan Lu, Franz P. Rischard
BACKGROUND:This study aims to assess the impact of sotatercept on exercise tolerance, exercise capacity, and right ventricular function in pulmonary arterial hypertension.METHODS:SPECTRA (Sotatercept Phase 2 Exploratory Clinical Trial in PAH) was a phase 2a, single-arm, open-label, multicenter exploratory study that evaluated the effects of sotatercept by invasive cardiopulmonary exercise testing in
-
GDMT Optimization, But Make It Patient-Centered: Understanding Patient Needs During Heart Failure Medication Discussions Circ. Heart Fail. (IF 9.7) Pub Date : 2024-04-06 Jocelyn S. Thompson
Increasing the use of guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF) is a current focus of research and quality improvement efforts. Combinations of at least 4 classes of dose-maximized medications have shown to markedly improve patient outcomes, but data indicate GDMT remains underprescribed.1,2 This is further exacerbated by nonadherence
-
Qualitative Analysis of Patient Decisional Needs for Medications to Treat Heart Failure Circ. Heart Fail. (IF 9.7) Pub Date : 2024-04-06 Ricky D. Turgeon, Saranee Fernando, Marc Bains, Jillianne Code, Nathaniel M. Hawkins, Sheri Koshman, Lynn Straatman, Mustafa Toma, Sean A. Virani, Blair J. MacDonald, M. Elizabeth Snow
BACKGROUND:The development of tools to support shared decision-making should be informed by patients’ decisional needs and treatment preferences, which are largely unknown for heart failure (HF) with reduced ejection fraction (HFrEF) pharmacotherapy decisions. We aimed to identify patients’ decisional needs when considering HFrEF medication options.METHODS:This was a qualitative study using semi-structured
-
Changes in Cardiac Function Following Fulminant Myocarditis Circ. Heart Fail. (IF 9.7) Pub Date : 2024-04-04 Koshiro Kanaoka, Kenji Onoue, Satoshi Terasaki, Michikazu Nakai, Yoshitaka Iwanaga, Yoshihiro Miyamoto, Yoshihiko Saito
BACKGROUND:The natural history of myocardial dysfunction in patients with fulminant myocarditis is poorly understood. This study aims to evaluate changes in cardiac function in patients with fulminant myocarditis using a nationwide registry in Japan.METHODS:This retrospective cohort study included patients with biopsy-proven fulminant myocarditis and available for left ventricular ejection fraction
-
Iron Deficiency, Anemia, and Iron Supplementation in Patients With Heart Failure: A Population-Level Study Circ. Heart Fail. (IF 9.7) Pub Date : 2024-04-04 Muizz Wahid, Sunjidatul Islam, Nariman Sepehrvand, Douglas C. Dover, Finlay A. McAlister, Padma Kaul, Justin A. Ezekowitz
BACKGROUND:Studies have shown an association between iron deficiency (ID) and clinical outcomes in patients with heart failure (HF), irrespective of the presence of ID anemia (IDA). The current study used population-level data from a large, single-payer health care system in Canada to investigate the epidemiology of ID and IDA in patients with acute HF and those with chronic HF, and the iron supplementation
-
mTOR Inhibition Prolongs Survival and Has Beneficial Effects on Heart Function After Onset of Lamin A/C Gene Mutation Cardiomyopathy in Mice Circ. Heart Fail. (IF 9.7) Pub Date : 2024-04-03 Wei Wu, Qi Jin, Cecilia Östlund, Kurenai Tanji, Ji-Yeon Shin, Jiying Han, Cheng-Shiun Leu, Jared Kushner, Howard J. Worman
BACKGROUND:Mutations in LMNA encoding nuclear envelope proteins lamin A/C cause dilated cardiomyopathy. Activation of the AKT/mTOR (RAC-α serine/threonine-protein kinase/mammalian target of rapamycin) pathway is implicated as a potential pathophysiologic mechanism. The aim of this study was to assess whether pharmacological inhibition of mTOR signaling has beneficial effects on heart function and prolongs
-
Targeted Gene Deletion or Antagonism of the Prostaglandin E2 EP3 Receptor Protects Against Cardiac Injury Postmyocardial Infarction Circ. Heart Fail. (IF 9.7) Pub Date : 2024-03-25 Timothy D. Bryson, Shaheen Y. Bhat, Carlin Moore, David Taube, Jiang Xu, Edward Peterson, Pamela Harding
BACKGROUND:Prostaglandin E2 acts through 4 G-protein-coupled receptors (EP1–EP4). We previously reported that activation of the EP3 receptor reduces cardiac contractility, and its expression increases after a myocardial infarction (MI), mediating the reduction in cardiac function. In contrast, cardiac overexpression of the EP4 receptor in MI substantially improves cardiac function. Moreover, we recently
-
Multi-Ethnic Study of Atherosclerosis Early Heart Failure Study: Rationale, Design, and Baseline Characteristics Circ. Heart Fail. (IF 9.7) Pub Date : 2024-03-08 Lauren Beussink-Nelson, Benjamin H. Freed, Julio A. Chirinos, Peter H. Brubaker, Dalane W. Kitzman, Joseph Yeboah, Sylvia E. Rosas, Mo Hu, João A.C. Lima, Jay Pandit, Alain G. Bertoni, Sanjiv J. Shah
Background:Current prevalence estimates of heart failure (HF) are primarily based on self-report or HF hospitalizations. There is an unmet need to define the prevalence and pathogenesis of early symptomatic HF, which may be undiagnosed and precedes HF hospitalization.Methods:The MESA (Multi-Ethnic Study of Atherosclerosis) Early HF study was conducted during MESA exam 6 to determine the prevalence
-
Impact of Advanced Therapy Centers on Characteristics and Outcomes of Heart Failure Admissions Circ. Heart Fail. (IF 9.7) Pub Date : 2024-03-08 Daniel Y. Lu, Jaya Kanduri, Ilhwan Yeo, Parag Goyal, Udhay Krishnan, Evelyn M. Horn, Maria G. Karas, Irina Sobol, David T. Majure, Yoshifumi Naka, Robert M. Minutello, Jim W. Cheung, Nir Uriel, Luke K. Kim
BACKGROUND:Although much attention has been paid to admission and transfer patterns for cardiogenic shock, contemporary data are lacking on decompensated heart failure (HF) admissions and transfers and the impact of advanced therapy centers (ATCs) on outcomes.METHODS:HF hospitalizations were obtained from the Nationwide Readmissions Database 2016 to 2019. Centers performing at least 1 heart transplant
-
Genetic Testing Yield and Clinical Characteristics of Hypertrophic Cardiomyopathy in Understudied Ethnic Groups: Insights From a New Zealand National Registry Circ. Heart Fail. (IF 9.7) Pub Date : 2024-03-08 Nikki J. Earle, Annika Winbo, Jackie Crawford, Miriam Wheeler, Rachael Stiles, Tom Donoghue, Martin K. Stiles, Ian Hayes, Luciana Marcondes, Andrew Martin, Jonathan R. Skinner
BACKGROUND:Aotearoa/New Zealand has a multiethnic population. Patients with hypertrophic cardiomyopathy (HCM) are enrolled in the national Cardiac Inherited Diseases Registry New Zealand. Here, we report the characteristics of Cardiac Inherited Diseases Registry New Zealand HCM probands with and without pathogenic or likely pathogenic (P/LP) genetic variants for HCM, and assess genetic testing yield
-
High-Intensity Care Versus GDMT Titration: Which Rapidly Improves Health Status in Patients With Heart Failure? Circ. Heart Fail. (IF 9.7) Pub Date : 2024-03-06 Nosheen Reza
Patient-reported health status, an important measure of cardiovascular health, encompasses symptom burden, functional status, and health-related quality of life.1 To patients with symptomatic heart failure (HF), improvement in fatigue, dyspnea, and depression have been shown to be of greater importance than achieving longer survival.2 Moreover, patient-reported health status is an independent predictor
-
Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial Circ. Heart Fail. (IF 9.7) Pub Date : 2024-03-06 Jelena Čelutkienė, Kamilė Čerlinskaitė-Bajorė, Gad Cotter, Christopher Edwards, Marianna Adamo, Mattia Arrigo, Marianela Barros, Jan Biegus, Ovidiu Chioncel, Alain Cohen-Solal, Albertino Damasceno, Rafael Diaz, Gerasimos Filippatos, Etienne Gayat, Antoine Kimmoun, Valentine Léopold, Marco Metra, Maria Novosadova, Matteo Pagnesi, Peter S. Pang, Piotr Ponikowski, Hadiza Saidu, Karen Sliwa, Koji Takagi
BACKGROUND:This analysis provides details on baseline and changes in quality of life (QoL) and its components as measured by EQ-5D-5L questionnaire, as well as association with objective outcomes, applying high-intensity heart failure (HF) care in patients with acute HF.METHODS:In STRONG-HF trial (Safety, Tolerability, and Efficacy of Rapid Optimization, Helped by NT-proBNP Testing, of Heart Failure
-
Biallelic Loss of Function Variants in Myocardial Zonula Adherens Protein Gene (MYZAP) Cause a Severe Recessive Form of Dilated Cardiomyopathy Circ. Heart Fail. (IF 9.7) Pub Date : 2024-03-04 Juan Pablo Ochoa, Laura Lalaguna, Jesús G. Mirelis, Fernando Dominguez, Esther Gonzalez-Lopez, Clara Salas, Gaston Roustan, Kathryn A. McGurk, Sean L. Zheng, Paul J.R. Barton, James S. Ware, María Victoria Gómez-Gaviro, Enrique Lara-Pezzi, Pablo Garcia-Pavia
Dilated cardiomyopathy (DCM) is the most frequent cause of heart failure in the young and the leading cause of transplantation. Almost half of the cases have a familial (hereditary) component, but even in familial cases, the diagnostic yield of genetic testing is lower than <40%.1Myocardial zonula adherens protein (MYZAP) gene encodes a protein widely expressed in cardiac tissue, being an emerging
-
Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF Circ. Heart Fail. (IF 9.7) Pub Date : 2024-03-04 Chris J. Kapelios, Stephen J. Greene, Robert J. Mentz, Uchechukwu Ikeaba, Daniel Wojdyla, Kevin J. Anstrom, Eric L. Eisenstein, Bertram Pitt, Eric J. Velazquez, James C. Fang, TRANSFORM-HF Investigators
BACKGROUND:The TRANSFORM-HF trial (Torsemide Comparison With Furosemide for Management of Heart Failure) found no significant difference in all-cause mortality or hospitalization among patients randomized to a strategy of torsemide versus furosemide following a heart failure (HF) hospitalization. However, outcomes and responses to some therapies differ by left ventricular ejection fraction (LVEF).
-
Metabolomic Association and Risk Prediction With Heart Failure in Older Adults Circ. Heart Fail. (IF 9.7) Pub Date : 2024-03-01 Guning Liu, Ngoc Quynh H. Nguyen, Kari E. Wong, Sunil K. Agarwal, Eric Boerwinkle, Patricia P. Chang, Brian L. Claggett, Laura R. Loehr, Jianzhong Ma, Kunihiro Matsushita, Carlos J. Rodriguez, Joseph S. Rossi, Stuart D. Russell, R. Brandon Stacey, Amil M. Shah, Bing Yu
BACKGROUND:Older adults have markedly increased risks of heart failure (HF), specifically HF with preserved ejection fraction (HFpEF). Identifying novel biomarkers can help in understanding HF pathogenesis and improve at-risk population identification. This study aimed to identify metabolites associated with incident HF, HFpEF, and HF with reduced ejection fraction and examine risk prediction in older
-
You Are Where You Eat: The Local Environment and Risk of Heart Failure Circ. Heart Fail. (IF 9.7) Pub Date : 2024-02-27 Elissa Driggin, Ersilia M. DeFilippis
The prevalence of heart failure (HF) in the United States is increasing to an estimated 8.5 million by the year 2030.1 Although we have made significant strides in our armamentarium of medical and device therapy for the prevention and treatment of HF, there remains an overall lack of attention to environmental, socioeconomic, and lifestyle factors that may mitigate the risk of incident HF. These environmental
-
Aerobic Exercise Attenuates Pressure Overload–Induced Myocardial Remodeling and Myocardial Inflammation via Upregulating miR-574-3p in Mice Circ. Heart Fail. (IF 9.7) Pub Date : 2024-02-27 Qiao-Ying Chen, Yi-Na Jiang, Xuan Guan, Fang-Fang Ren, Shu-Jie Wu, Mao-Ping Chu, Lian-Pin Wu, Teng-Fang Lai, Lei Li
BACKGROUND:Exercise training can promote cardiac rehabilitation, thereby reducing cardiovascular disease mortality and hospitalization rates. MicroRNAs (miRs) are closely related to heart disease, among which miR-574-3p plays an important role in myocardial remodeling, but its role in exercise-mediated cardioprotection is still unclear.METHODS:A mouse myocardial hypertrophy model was established by
-
Ready-to-Eat Food Environments and Risk of Incident Heart Failure: A Prospective Cohort Study Circ. Heart Fail. (IF 9.7) Pub Date : 2024-02-27 Qiaochu Xue, Xiang Li, Hao Ma, Xuan Wang, Yoriko Heianza, Lu Qi
BACKGROUND:Food environments have been linked to cardiovascular diseases; however, few studies have assessed the relationship between food environments and the risk of heart failure (HF). We aimed to evaluate the association between ready-to-eat food environments and incident HF at an individual level in a large prospective cohort.METHODS:Exposure to ready-to-eat food environments, comprising pubs
-
Racial Differences in Donor-Derived Cell-Free DNA and Mitochondrial DNA After Heart Transplantation, on Behalf of the GRAfT Investigators Circ. Heart Fail. (IF 9.7) Pub Date : 2024-02-20 Palak Shah, Sean Agbor-Enoh, Seiyon Lee, Temesgen E. Andargie, Shashank S. Sinha, Hyesik Kong, Lawrence Henry, Woojin Park, Erick McNair, Inna Tchoukina, Keyur B. Shah, Samer S. Najjar, Steven Hsu, Maria E. Rodrigo, Moon Kyoo Jang, Charles Marboe, Gerald J. Berry, Hannah A. Valantine, on behalf of the GRAfT Investigators
BACKGROUND:Black heart transplant patients are at higher risk of acute rejection (AR) and death than White patients. We hypothesized that this risk may be associated with higher levels of donor-derived cell-free DNA (dd-cfDNA) and cell-free mitochondrial DNA.METHODS:The Genomic Research Alliance for Transplantation is a multicenter, prospective, longitudinal cohort study. Sequencing was used to quantitate
-
Failing to Make the Grade: Conventional Cardiac Allograft Rejection Grading Criteria Are Inadequate for Predicting Rejection Severity Circ. Heart Fail. (IF 9.7) Pub Date : 2024-02-13 Sara Arabyarmohammadi, Cai Yuan, Vidya Sankar Viswanathan, Priti Lal, Michael D. Feldman, Pingfu Fu, Kenneth B. Margulies, Anant Madabhushi, Eliot G. Peyster
BACKGROUND:Cardiac allograft rejection is the leading cause of early graft failure and is a major focus of postheart transplant patient care. While histological grading of endomyocardial biopsy samples remains the diagnostic standard for acute rejection, this standard has limited diagnostic accuracy. Discordance between biopsy rejection grade and patient clinical trajectory frequently leads to both
-
Sex and Age Differences in the Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Heart Failure: A Prospective Cohort Study Circ. Heart Fail. (IF 9.7) Pub Date : 2024-02-13 Shouling Wu, Yuhao Li, Yijun Zhang, Xin Su, Yingting Zuo, Guojuan Chen, Guozheng Xu, Shuohua Chen, Yan He, Anxin Wang
BACKGROUND:Metabolic dysfunction-associated fatty liver disease (MAFLD) is a risk factor for heart failure (HF) occurrence, but it remains unclear whether the association between MAFLD and HF differs in different sexes and ages.METHODS:A total of 96 576 participants of Kailuan Study were included. MAFLD was defined as presence of hepatic steatosis and metabolic dysfunction and classified as mild and
-
Enhancing the Prediction of Cardiac Allograft Vasculopathy Using Intravascular Ultrasound and Machine Learning: A Proof of Concept Circ. Heart Fail. (IF 9.7) Pub Date : 2024-02-05 Yasbanoo Moayedi, Eduard Rodenas-Alesina, Emily Somerset, Chun Po S. Fan, Erik Henricksen, Natasha Aleksova, Filio Billia, Sharon Chih, Heather J. Ross, Jeffrey J. Teuteberg
BACKGROUND:Cardiac allograft vasculopathy (CAV) is the leading cause of late graft dysfunction in heart transplantation. Building on previous unsupervised learning models, we sought to identify CAV clusters using serial maximal intimal thickness and baseline clinical risk factors to predict the development of early CAV.METHODS:This is a single-center retrospective study including adult heart transplantation
-
Waitlist Outcomes in Candidates With Rare Causes of Heart Failure After Implementation of the 2018 French Heart Allocation Scheme Circ. Heart Fail. (IF 9.7) Pub Date : 2024-02-01 Camille Legeai, Guillaume Coutance, Christelle Cantrelle, Carine Jasseron, Marylou Para, Laurent Sebbag, Pascal Battistella, François Kerbaul, Richard Dorent
BACKGROUND:In 2018, an algorithm-based allocation system for heart transplantation (HT) was implemented in France. Its effect on access to HT of patients with rare causes of heart failure (HF) has not been assessed.METHODS:In this national study, including adults listed for HT between 2018 and 2020, we analyzed waitlist and posttransplant outcomes of candidates with rare causes of HF (restrictive cardiomyopathy
-
Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure With Preserved Ejection Fraction Circ. Heart Fail. (IF 9.7) Pub Date : 2024-02-01 Joe David Azzo, Marie-Joe Dib, Loukas Zagkos, Lei Zhao, Zhaoqing Wang, Ching-Pin Chang, Christina Ebert, Oday Salman, Sushrima Gan, Payman Zamani, Jordana B. Cohen, Vanessa van Empel, A. Mark Richards, Ali Javaheri, Douglas L. Mann, Ernst R. Rietzschel, Peter H. Schafer, Dietmar A. Seiffert, Dipender Gill, Stephen Burgess, Francisco Ramirez-Valle, David A. Gordon, Thomas P. Cappola, Julio A. Chirinos
Background:NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels are variably elevated in heart failure with preserved ejection fraction (HFpEF), even in the presence of increased left ventricular filling pressures. NT-proBNP levels are prognostic in HFpEF and have been used as an inclusion criterion for several recent randomized clinical trials. However, the underlying biologic differences
-
Estimation of Right Atrial Pressure by Ultrasound-Assessed Jugular Vein Distensibility in Patients With Heart Failure Circ. Heart Fail. (IF 9.7) Pub Date : 2024-02-01 Enrico Ammirati, Davide Marchetti, Giada Colombo, Pierpaolo Pellicori, Piero Gentile, Luciana D’Angelo, Gabriella Masciocco, Alessandro Verde, Francesca Macera, Dario Brunelli, Lucia Occhi, Francesco Musca, Enrico Perna, Davide P. Bernasconi, Antonella Moreo, Paolo G. Camici, Marco Metra, Fabrizio Oliva, Andrea Garascia
BACKGROUND:Clinical evaluation of central venous pressure is difficult, depends on experience, and is often inaccurate in patients with chronic advanced heart failure. We assessed the ultrasound-assessed internal jugular vein (JV) distensibility by ultrasound as a noninvasive tool to identify patients with normal right atrial pressure (RAP ≤7 mm Hg) in this population.METHODS:We measured JV distensibility
-
Trends and Outcomes Associated With Bariatric Surgery and Pharmacotherapies With Weight Loss Effects Among Patients With Heart Failure and Obesity Circ. Heart Fail. (IF 9.7) Pub Date : 2024-01-26 Amgad Mentias, Milind Y. Desai, Ali Aminian, Kershaw V. Patel, Neil Keshvani, Subodh Verma, Leslie Cho, Miriam Jacob, Paulino Alvarez, A. Michael Lincoff, Harriette G.C. Van Spall, Carolyn S.P. Lam, Javed Butler, Steven E. Nissen, Ambarish Pandey
BACKGROUND:Utilization patterns of bariatric surgery among older patients with heart failure (HF), and the associations with cardiovascular outcomes, are not well known.METHODS:Medicare beneficiaries with HF and at least class II obesity from 2013 to 2020 were identified with Medicare Provider Analysis and Review 100% inpatient files and Medicare 5% outpatient files. Patients who underwent bariatric
-
Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial Circ. Heart Fail. (IF 9.7) Pub Date : 2024-01-22 Josephine Harrington, Robert J. Mentz, Frank W. Rockhold, Jyotsna Garg, Javed Butler, Carmine G. De Pasquale, Justin A. Ezekowitz, Gregory D. Lewis, Eileen O’Meara, Piotr Ponikowski, Richard W. Troughton, Yee W. Wong, Robert Adamczyk, Tatyana Storie, Nicole Blackman, Adrian F. Hernandez
BACKGROUND:Clinical trials in heart failure (HF) traditionally use time-to-event analyses focusing on death and hospitalization for HF. These time-to-first event analyses may have more limited abilities to assess the probability of benefiting from a therapy, especially if that benefit manifests as improved functional status rather than reduced risk of death or HF hospitalization. Hierarchical end points
-
Neurocognitive Impairments and Their Improvement Following Exercise and Dietary Interventions in Older Patients With Heart Failure With Preserved Ejection Fraction. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-12-01 Christopher L Schaich,Timothy M Hughes,Dalane W Kitzman,Youngkyoo Jung,Haiying Chen,Barbara J Nicklas,Denise K Houston,Peter H Brubaker,Anthony J A Molina,Christina E Hugenschmidt
-
Epicardial Fat Paradox and Differential Effects of GLP-1 Receptor Agonists Across Heart Failure Phenotypes. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-11-27 Mainak Banerjee
-
HeartMate 3 Left Ventricular Assist Device Improves Long-Term Cerebral Hemodynamics. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-11-06 Christopher G Favilla,Sarah Carter,Pavan Atluri,Navpreet Reehal,Michael V Genuardi
-
An Economic Modeling Analysis of an Intensive GDMT Optimization Program in Hospitalized Heart Failure Patients. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-11-06 Neal M Dixit,Neil U Parikh,Boback Ziaeian,Gregg C Fonarow
Background: The STRONG-HF trial demonstrated substantial reductions in the composite of mortality and morbidity over 6 months among hospitalized heart failure patients who were randomized to intensive guideline-directed medical therapy (GDMT) optimization compared to usual care. Whether an intensive GDMT optimization program would be cost-effective for patients with heart failure with reduced ejection
-
Longitudinal Trends in Donor and Recipient Risk Profile, and Clinical Outcomes, for Donation After Circulatory Death Heart Transplantation. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-11-06 Joseph B Lerman,Daniel Marshall Guidot,Cynthia L Green,Chetan B Patel,Richa Agarwal,Nancy K Sweitzer,Jeffrey Keenan,Carmelo A Milano,Jacob N Schroder,Adam D DeVore
-
Detailed Assessment of the "I Need Help" Criteria in Patients With Heart Failure: Insights From the HELP-HF Registry. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-11-01 Matteo Pagnesi,Daniele Ghiraldin,Enrico Vizzardi,Mauro Chiarito,Davide Stolfo,Luca Baldetti,Marianna Adamo,Carlo Mario Lombardi,Riccardo Maria Inciardi,Daniela Tomasoni,Ferdinando Loiacono,Marta Maccallini,Alessandro Villaschi,Gaia Gasparini,Marco Montella,Stefano Contessi,Daniele Cocianni,Maria Perotto,Giuseppe Barone,Samantha Sartori,Beth A Davison,Marco Merlo,Alberto Maria Cappelletti,Gianfranco
BACKGROUND The "I Need Help" markers have been proposed to identify patients with advanced heart failure (HF). We evaluated the prognostic impact of these markers on clinical outcomes in a real-world, contemporary, multicenter HF population. METHODS We included consecutive patients with HF and at least 1 high-risk "I Need Help" marker from 4 centers. The impact of the cumulative number of "I Need Help"
-
Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-10-27 Toru Kondo,Jawad H Butt,James P Curtain,Pardeep S Jhund,Kieran F Docherty,Brian L Claggett,Muthiah Vaduganathan,Erasmus Bachus,Adrian F Hernandez,Carolyn S P Lam,Silvio E Inzucchi,Felipe A Martinez,Rudolf A de Boer,Mikhail N Kosiborod,Akshay S Desai,Lars Køber,Piotr Ponikowski,Marc S Sabatine,Scott D Solomon,John J V McMurray
BACKGROUND Although elevated resting heart rate (HR) is associated with a higher risk of cardiovascular events in patients with heart failure with reduced ejection fraction in sinus rhythm (SR), the relationship between HR and outcomes among patients with heart failure with mildly reduced ejection fraction/heart failure with preserved ejection fraction and in those with atrial fibrillation (AF) is
-
Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-10-23 Gregory D Lewis,Kensey Gosch,Laura P Cohen,Michael E Nassif,Sheryl L Windsor,Barry A Borlaug,Dalane W Kitzman,Sanjiv J Shah,Taiyeb Khumri,Guillermo Umpierrez,Sumant Lamba,Kavita Sharma,Sadiya S Khan,Mikhail N Kosiborod,Andrew J Sauer
BACKGROUND Heart failure with preserved ejection fraction is associated with significant functional limitations, yet treatments for improving exercise performance have been elusive. We sought to explore the association between prespecified patient characteristics and changes in 6-minute walk distance that constitute a clinically significant response to dapagliflozin. METHODS We performed a responder
-
Will the SGLT2i Responders Please Stand Up? Circ. Heart Fail. (IF 9.7) Pub Date : 2023-10-23 Kane Banner,Daniel N Silverman
-
Palliative Care for Patients With Heart Failure With Preserved Ejection Fraction. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-10-23 Sarah Godfrey,Yilong Peng,Nicholas Lorusso,Melanie Sulistio,Robert J Mentz,Ambarish Pandey,Haider Warraich
Heart failure with preserved ejection fraction (HFpEF) has become the leading form of heart failure worldwide, particularly among elderly patient populations. HFpEF is associated with significant morbidity and mortality that may benefit from incorporation of palliative care (PC). Patients with HFpEF have similarly high mortality rates to patients with heart failure with reduced ejection fraction. PC
-
Unmasking Transthyretin Cardiac Amyloidosis Following Transcatheter Aortic Valve Implantation. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-09-28 Ryo Nishikawa,Toshiyuki Yano,Nobuaki Kokubu,Atsuko Muranaka,Naoto Murakami,Yosuke Ido,Yuichi Nakamura,Masato Furuhashi
-
Diabetes and Implantable Cardioverter Defibrillator in Nonischemic Systolic Heart Failure: An Extended Follow-Up Analysis of DANISH. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-09-27 Seiko Nakajima Doi,Jens Jakob Thune,Jens Cosedis Nielsen,Jens Haarbo,Lars Videbæk,Rasmus Rørth,Søren Lund Kristensen,Niels Eske Bruun,Finn Gustafsson,Hans Eiskjær,Christian Hassager,Jesper Hastrup Svendsen,Dan Eik Høfsten,Christian Torp-Pedersen,Steen Pehrson,Lars Køber,Jawad Haider Butt
-
MMP-2 Associates With Incident Heart Failure and Atrial Fibrillation: The ARIC Study. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-09-27 Leo F Buckley,Ali M Agha,Pranav Dorbala,Brian L Claggett,Bing Yu,Aliza Hussain,Vijay Nambi,Lin Yee Chen,Kunihiro Matsushita,Ron C Hoogeveen,Christie M Ballantyne,Amil M Shah
BACKGROUND MMP (matrix metalloproteinase)-2 participates in extracellular matrix regulation and may be involved in heart failure (HF), atrial fibrillation (AF), and coronary heart disease. METHODS Among the 4693 ARIC study (Atherosclerosis Risk in Communities) participants (mean age, 75±5 years; 42% women) without prevalent HF, multivariable Cox proportional hazard models were used to estimate associations
-
Microvascular Dysfunction as a Possible Link Between Heart Failure and Cognitive Dysfunction. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-09-26 Elizabeth Hillier,Jason Covone,Kady Fischer,Hao Yu Chen,Tarik Hafyane,Matthias G Friedrich
BACKGROUND Microvascular function in the brain and heart may play an important role in the course of patients with heart failure (HF), but its relationship with ventricular and cognitive function is not well understood. We hypothesized that microvascular function in HF is closely related to both, cardiac and cognitive function. METHODS In healthy controls and symptomatic patients with HF (New York
-
Obesity-Related Biomarkers Are Associated With Exercise Intolerance and HFpEF. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-09-13 Mariana F Ramirez,Emily S Lau,Juhi K Parekh,Abigail S Pan,Ndidi Owunna,Dongyu Wang,Jenna N McNeill,Rajeev Malhotra,Matthew Nayor,Gregory D Lewis,Jennifer E Ho
BACKGROUND Obesity and adiposity are associated with an increased risk of heart failure with preserved ejection fraction (HFpEF); yet, specific underlying mechanisms remain unclear. We sought to examine the association of obesity-related biomarkers including adipokines (leptin, resistin, adiponectin), inflammatory markers (CRP [C-reactive protein], IL-6 [interleukin-6]), and insulin resistance (HOMA-IR)
-
Hemodynamic Manifestations of Concomitant Radiation-Induced Tricuspid Regurgitation and Pericardial Constriction Undergoing Transcatheter Tricuspid Valve Repair. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-09-13 Katie P Truong,Marcella Calfon Press,Peyman Benharash,Saibal Kar,Norman E Lepor,Gabriel Vorobiof,Eric H Yang
-
Long-Term Effects of Pulmonary Endarterectomy on Right Ventricular Stiffness and Fibrosis in Chronic Thromboembolic Pulmonary Hypertension. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-09-07 Natalia J Braams,Azar Kianzad,Jessie van Wezenbeek,Jeroen N Wessels,Samara M A Jansen,Stine Andersen,Anco Boonstra,Esther J Nossent,J Tim Marcus,Ahmed A Bayoumy,Clarissa Becher,Marie-José Goumans,Asger Andersen,Anton Vonk Noordegraaf,Frances S de Man,Harm Jan Bogaard,Lilian J Meijboom
BACKGROUND Surgical removal of thromboembolic material by pulmonary endarterectomy (PEA) leads within months to the improvement of right ventricular (RV) function in the majority of patients with chronic thromboembolic pulmonary hypertension. However, RV mass does not always normalize. It is unknown whether incomplete reversal of RV remodeling results from extracellular matrix expansion (diffuse interstitial
-
Modulation of Pulsatile Left Ventricular Afterload by Renal Denervation in Heart Failure With Preserved Ejection Fraction. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-08-30 Karl-Philipp Rommel,Stamatia Pagoulatou,Karl-Patrik Kresoja,Sebastian Rosch,Anne Rebecca Schöber,Maximilian von Roeder,Holger Thiele,Karl Fengler,Nikolaos Stergiopulos,Philipp Lurz
BACKGROUND Arterial stiffening contributes to hemodynamic derangements in heart failure with preserved ejection fraction (HFpEF). We sought to investigate the impact of renal denervation on pulsatile left ventricular loading in patients with HFpEF and hypertensive patients without heart failure (control). METHODS Patients underwent renal denervation for treatment of hypertension and were followed up
-
Hospital at Home as a Treatment Strategy for Worsening Heart Failure. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-08-30 Hubert B Haywood,Gregg C Fonarow,Muhammad Shahzeb Khan,Harriette G C Van Spall,Alanna A Morris,Michael E Nassif,Michelle M Kittleson,Javed Butler,Stephen J Greene
Hospital at home (HaH) is an innovative care model that may be particularly suited for heart failure (HF). Outpatient visits and inpatient care have been the 2 traditional settings for HF care, yet may not match the social and medical needs of patients at all times. Alternative models such as HaH may represent an effective and patient-centered option for select patients with worsening HF. To date,
-
Pressure Overload-Induced Cardiac Hypertrophy Stimulates Tumor Growth in Tumor-Prone ApcMin Mice. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-08-23 Sanne de Wit,Joseph Pierre Aboumsallem,Canxia Shi,Elisabeth M Schouten,Valentina Bracun,Wouter C Meijers,Herman H W Silljé,Rudolf A de Boer
-
PHM in Heart Transplantation: From Predicted Heart Mass to Practical Heart Matching. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-08-21 Joel D Schilling,Amit Pawale
-
Predicted Heart Mass: A Tale of 2 Ventricles. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-08-21 Eduard Ródenas-Alesina,Farid Foroutan,Chun-Po Fan,Josef Stehlik,Ina Bartlett,Maxime Tremblay-Gravel,Natasha Aleksova,Vivek Rao,Robert J H Miller,Kiran K Khush,Heather J Ross,Yasbanoo Moayedi
BACKGROUND Total predicted heart mass (PHM) is the recommended metric to assess donor-recipient size matching in patients undergoing heart transplantation. Separately measuring right ventricular (RV) and left ventricular (LV) PHM may improve risk prediction of 1-year graft failure. METHODS Adult heart transplant recipients from the UNOS database from 2000 to 2018 were included in the study. LV and
-
Hemodynamic Consequences of Long-Term Continuous Flow: The Importance of the Right Ventricular-Aortic Valve Interactions. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-08-14 Jonathan Grinstein,Jennifer A Cowger,Mark N Belkin,Brian A Houston,Ryan J Tedford
-
Serial Quantitative Assessment of Myocardial Blood Flow With 13N-Ammonia Positron Emission Tomography in a Symptomatic Patient With Tachycardia-Induced Cardiomyopathy. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-08-02 Shiro Miura,Atsutaka Okizaki,Osamu Manabe,Chihoko Miyazaki,Takehiro Yamashita
-
Myocardial Fibrosis and Cardiomyopathy Risk: A Genetic Link in the MESA. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-08-01 Mahsima Shabani,Min Wang,Gregory D Jenkins,Jerome I Rotter,Stephen S Rich,Anthony Batzler,Kent D Taylor,Josyf C Mychaleckyj,Duan Liu,Joao A C Lima,Naveen L Pereira
BACKGROUND Common genetic variants are associated with risk for hypertrophic cardiomyopathy and dilated cardiomyopathy and with left ventricular (LV) traits. Whether these variants are associated with myocardial fibrosis, an important pathophysiological mediator of cardiomyopathy, is unknown. METHODS Multi-Ethnic Study of Atherosclerosis participants with T1-mapping cardiac magnetic resonance imaging
-
Cardiac Autoantibodies Against Cardiac Troponin I in Post-Myocardial Infarction Heart Failure: Evaluation in a Novel Murine Model and Applications in Therapeutics. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-07-31 Shun Furusawa,Masataka Ikeda,Tomomi Ide,Takuya Kanamura,Hiroko Deguchi Miyamoto,Ko Abe,Kosei Ishimaru,Masatsugu Watanabe,Yoshitomo Tsutsui,Ryo Miyake,Satoshi Fujita,Takeshi Tohyama,Shouji Matsushima,Yoshihiro Baba,Hiroyuki Tsutsui
BACKGROUND Cardiac autoantibodies (cAAbs) are involved in the progression of adverse cardiac remodeling in heart failure (HF). However, our understanding of cAAbs in HF is limited owing to the absence of relevant animal models. Herein, we aimed to establish and characterize a murine model of cAAb-positive HF after myocardial infarction (MI), thereby facilitating the development of therapeutics targeting
-
Trends and Outcomes of Cardiogenic Shock in Patients With End-Stage Renal Disease: Insights From USRDS Database. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-07-28 Tarun Dalia,Suveenkrishna Pothuru,Wan-Chi Chan,Harsh Mehta,Amandeep Goyal,Hassan Farhoud,Ilham Boda,Anureet Malhotra,Andrija Vidic,Aniket S Rali,Thomas C Hanff,Kamal Gupta,James C Fang,Zubair Shah
BACKGROUND There is a paucity of data regarding epidemiology, temporal trends, and outcomes of patients with cardiogenic shock (CS) and end-stage renal disease (chronic kidney disease stage V on hemodialysis). METHODS This is a retrospective cohort study using the United States Renal Data System database from January 1, 2006 to December 31, 2019. We analyzed trends of CS, percutaneous mechanical support
-
Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of Vericiguat. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-07-28 Paul W Armstrong,Yinggan Zheng,Lars H Lund,Javed Butler,Richard W Troughton,Michele Emdin,Carolyn S P Lam,Piotr Ponikowski,Robert O Blaustein,Christopher M O'Connor,Lothar Roessig,Adriaan A Voors,Justin A Ezekowitz,Cynthia M Westerhout,
BACKGROUND Selecting high-risk patients with heart failure with potentially modifiable cardiovascular events is a priority. Our objective was to evaluate NT-proBNP (N-terminal pro-B-type natriuretic peptide) changes during a 30-day screening to establish (1) the frequency and direction of changes; (2) whether a relationship exists between changes in NT-proBNP and the primary composite outcome of cardiovascular
-
Left Ventricular Gene Expression in Heart Failure With Preserved Ejection Fraction-Profibrotic and Proinflammatory Pathways and Genes. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-07-27 Bo Ye,Amy D Bradshaw,Juan E Abrahante,Julie A Dragon,Tim N Häußler,Stephen P Bell,Fuyuki Hirashima,Martin LeWinter,Michael R Zile,Markus Meyer
BACKGROUND Heart failure with preserved ejection fraction (HFpEF) is increasingly prevalent and has few treatments. The molecular mechanisms and resultant signaling pathways that underlie the development of HFpEF are poorly defined. It has been proposed that activation of proinflammatory pathways plays a role in the development of cardiac fibrosis. The signature of gene expression (transcriptome) of
-
Acute Pulmonary Edema During Impella RP Support: Too Much of a Good Thing. Circ. Heart Fail. (IF 9.7) Pub Date : 2023-07-27 Federico Moccetti,Andreas Bloch,Stefan Toggweiler,Florim Cuculi